Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68


Autophagy in nuclear receptor PPARgamma-deficient mouse prostatic carcinogenesis.

Jiang M, Jerome WG, Hayward SW.

Autophagy. 2010 Jan;6(1):175-6. Epub 2010 Jan 18. Review.


Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW.

Cell Death Differ. 2010 Mar;17(3):469-81. doi: 10.1038/cdd.2009.148. Epub 2009 Oct 16.


PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation.

Strand DW, Jiang M, Murphy TA, Yi Y, Konvinse KC, Franco OE, Wang Y, Young JD, Hayward SW.

Cell Death Dis. 2012 Aug 9;3:e361. doi: 10.1038/cddis.2012.99.


Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway.

Fujisawa T, Nakajima A, Fujisawa N, Takahashi H, Ikeda I, Tomimoto A, Yonemitsu K, Nakajima N, Kudo C, Wada K, Kubota N, Terauchi Y, Kadowaki T, Nakagama H, Blumberg RS.

J Pharmacol Sci. 2008 Apr;106(4):627-38. Epub 2008 Apr 5.


3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.

Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, Pestell RG, Glazer RI.

Mol Endocrinol. 2006 Feb;20(2):268-78. Epub 2005 Sep 8.


Overexpression of PPARγ specifically in pancreatic β-cells exacerbates obesity-induced glucose intolerance, reduces β-cell mass, and alters islet lipid metabolism in male mice.

Hogh KL, Craig MN, Uy CE, Nygren H, Asadi A, Speck M, Fraser JD, Rudecki AP, Baker RK, Orešič M, Gray SL.

Endocrinology. 2014 Oct;155(10):3843-52. doi: 10.1210/en.2014-1076. Epub 2014 Jul 22.


Peroxisome proliferator-activated receptor gamma (PPARγ) in yellow catfish Pelteobagrus fulvidraco: molecular characterization, mRNA expression and transcriptional regulation by insulin in vivo and in vitro.

Zheng JL, Zhuo MQ, Luo Z, Pan YX, Song YF, Huang C, Zhu QL, Hu W, Chen QL.

Gen Comp Endocrinol. 2015 Feb 1;212:51-62. doi: 10.1016/j.ygcen.2014.12.020. Epub 2015 Jan 28.


Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver.

Yu S, Viswakarma N, Batra SK, Sambasiva Rao M, Reddy JK.

Biochimie. 2004 Nov;86(11):743-61.


Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.

Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noël D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L.

Mol Cell Biol. 2006 Oct;26(20):7561-74.


Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration.

Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW.

Am J Pathol. 2013 Feb;182(2):449-59. doi: 10.1016/j.ajpath.2012.10.007. Epub 2012 Dec 6.


Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.

Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, Wang S, Lam CN, Feng H, Zhao J, Cheng AS, To KF, Chan HL, Sung JJ.

Hepatology. 2010 Jun;51(6):2008-19. doi: 10.1002/hep.23550.


Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.

Fiatte C, Huin C, Bertin I, Lesuffleur T, Pluvinet A, Touche N, Plénat F, Dauça M, Domenjoud L, Schohn H.

Int J Oncol. 2006 Dec;29(6):1601-10.


Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.

Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1710-6.


Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.

Lin H, Yan J, Wang Z, Hua F, Yu J, Sun W, Li K, Liu H, Yang H, Lv Q, Xue J, Hu ZW.

Hepatology. 2013 Jan;57(1):171-82. doi: 10.1002/hep.25991.


PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.

Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY.

Oncogene. 2006 May 4;25(19):2736-47.


Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.

Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI.

Cancer Res. 2005 May 1;65(9):3950-7. Erratum in: Cancer Res. 2005 Jul 1;65(13):5989. Cancer Res. 2005 Oct 1;65(19):9108. Kopleovich, Levy [corrected to Kopelovich, Levy].


Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis.

Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, Zou B, Gu Q, Wang J, Pang R, Lan HY, Wong BC.

Cancer Res. 2009 Jun 1;69(11):4776-83. doi: 10.1158/0008-5472.CAN-08-4754. Epub 2009 May 19.


Cellular retinol-binding protein type III is a PPARgamma target gene and plays a role in lipid metabolism.

Zizola CF, Schwartz GJ, Vogel S.

Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1358-68. doi: 10.1152/ajpendo.90464.2008. Epub 2008 Oct 7.

Supplemental Content

Support Center